Stiefel to buy Connetics for $640M

Coral Gables, FL-based Stiefel Laboratories will fork over $640 million for Connetics Corporation. Stiefel develops a number of prescription and non-prescription dermatological products and through the buyout, will gain Connetics' advanced therapies and topical delivery technologies. The deal is expected to close in late 2006 or early 2007. Thomas G. Wiggans, chairman and CEO of Connetics, noted that, "The combination of Stiefel and Connetics will create the world's premier dermatology company with a strong global presence in both branded and generic markets, dozens of marketed products and the most robust development pipeline in the industry. After the combination, Stiefel Laboratories. will have more than 3,500 employees worldwide, with more than 30 subsidiaries and sales in more than 100 countries."

- see the press release for more on the deal

PLUS: Auriga Laboratories has licensed five prescription dermatology products from River's Edge Pharmaceuticals. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.